Bio
Product and technology leader with 25+ years of experience, learning across various technologies, company sizes, and product maturity levels, including in the life sciences, healthcare, research publishing, and intellectual property spaces at companies like Clarivate and GE Healthcare. With a focus on enterprise B2B software and a decade of experience working with AI technologies, one of Wes’ primary goals has been to help customers reduce the time and costs needed to complete workflows. Today’s AI technologies can be force-multipliers toward freeing up a customer’s time to work on higher-value activities.
What makes Norstella’s AI different?
Norstella’s proprietary data, curated by analysts for decades, combined with products built around a specific persona or job role. With our AI tools, just ask in plain language. Built for your workflow, not adapted from a generalist tool. Biopharma-specific charts and outputs, on enterprise-grade infrastructure.
What can pharma teams do now that was not possible two years ago?
Two years ago, customers were pulling data from multiple platforms, stitching together a competitive landscape in Excel, and hoping they hadn’t missed something. Today, with Atlas and the AI capabilities Norstella has been building into the Evaluate suite, they can ask a natural language question about a therapeutic area and get a synthesized answer that would have taken my team a week to build manually. The speed of insight has genuinely changed how they operate — customers are making portfolio decisions in days, not months.
How can AI accelerate the journey from pipeline to patient?
The place I see the biggest unlock is in the early ‘go/no-go’ decision — when you’re sitting on Phase II data and trying to model out the commercial opportunity against a crowded indication. Trial probability data layered with financial and patient-based forecasts used to require a dedicated analyst and two weeks. Now AI is doing that synthesis in real-time, which means the right assets move faster and the wrong ones get killed earlier — and both of those outcomes are good for our customers and for patients.